SCHEMBL2197635

SCHEMBL2197635

Cc1nn(-c2cccc(OC(F)(F)F)c2)c(C)c1C(=O)N1CCC(N(C)C)CC1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.53
CACNA1B Q00975 3/20 0.43
OPRM1 P35372 1/20 0.43
CACNA2D1 P54289 1/20 0.43
MAPT P10636 2/20 0.43
HSD11B1 P28845 1/20 0.43
RAB9A P51151 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
NPY5R Q15761 1/20 0.42
MGLL Q99685 1/20 0.42
NOTUM Q6P988 1/20 0.41
SCN9A Q15858 2/20 0.41
GPR119 Q8TDV5 1/20 0.41
SCN10A Q9Y5Y9 1/20 0.41
MAPK7 Q13164 1/20 0.41
L3MBTL3 Q96JM7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2200093 0.87 KMT2A (0.48) KMT2ACACNA1BNPSR1L3MBTL3
SCHEMBL2200002 0.87 KMT2A (0.47) KMT2ACACNA1BOPRM1CACNA2D1MAPT
SCHEMBL2201907 0.86 KMT2A (0.52) KMT2AMAPTHSD11B1RAB9ANPSR1
SCHEMBL2203102 0.85 KMT2A (0.45) KMT2ACACNA1BOPRM1CACNA2D1MAPT
SCHEMBL2203098 0.85 KMT2A (0.45) KMT2ACACNA1BOPRM1CACNA2D1MAPT
SCHEMBL2203058 0.85 KMT2A (0.52) KMT2AMAPTHSD11B1RAB9ANPSR1
SCHEMBL2200707 0.85 KMT2A (0.52) KMT2AMAPTHSD11B1RAB9ANPSR1
SCHEMBL2203158 0.84 KMT2A (0.51) KMT2AOPRM1CACNA2D1MAPTHSD11B1
SCHEMBL2200196 0.84 KMT2A (0.57) KMT2AMAPTRAB9ANPSR1NPY5R
SCHEMBL13973729 0.84 KMT2A (0.51) KMT2AOPRM1CACNA2D1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029963-A1 PYRAZOL DERIVATIVES CCR1, CCR3, CCRL2 KMT2A 4057/4885CACNA1B 2898/4885OPRM1 368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.